News | August 02, 2007

RF Ablation Not Effective in Certain Ventricular Tachycardias

August, 3, 2007 - In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), there is a high rate of recurrence following radiofrequency (RF) catheter ablation following electrophysiologic mapping, researchers report in the July 31st issue of the Journal of the American College of Cardiology.

"This study demonstrates that ventricular tachycardia in the setting of ARVD/C cannot be cured with RF catheter ablation," senior investigator Dr. Hugh Calkins told Reuters Health.

"These findings," he added, "also call into question the early use of RF ablation to treat ventricular tachycardia in this setting."

Dr. Calkins of the Johns Hopkins University School of Medicine in Baltimore and his colleagues note that previous studies of RF ablation for this inherited cardiomyopathy have yielded conflicting results.

To investigate further, the researchers followed 32 patients who had undergone at least one RF ablation procedure for ventricular tachycardia. In total, 48 procedures were performed. Of these, conventional mapping had been used for 38 procedures and the remaining ten employed three-dimensional electroanatomical mapping.

Seventy-seven per cent of the procedures resulted in ablation of ventricular tachycardias; these could not be re-induced with programmed electrical stimulation. However, clinical ventricular tachycardia was inducible in the other 23 per cent.

Overall, the researchers considered 46 per cent of the procedures to be successful, 31 per cent to be partially successful and 23 per cent of them to have failed. There was one procedure-related death.

The cumulative ventricular tachycardia recurrence-free survival rate was 75 per cent at six weeks, but this dropped to 25 per cent after 14 months. Cumulative recurrence-free survival had no significant association with the success or number of procedures, or with the mapping technique.

Until further data are available, the investigators recommend that "catheter ablation of ventricular tachycardia in patients with ARVD/C only be used as a palliative procedure to reduce the frequency of ventricular tachycardia episodes."

Source: Reuters
Author: David Douglas

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init